Glucotrack Stock Performance
| GCTK Stock | USD 0.07 0 4.79% |
The company retains a Market Volatility (i.e., Beta) of 1.37, which attests to a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, GlucoTrack will likely underperform. At this point, GlucoTrack has a negative expected return of -2.37%. Please make sure to check out GlucoTrack's maximum drawdown, accumulation distribution, as well as the relationship between the Accumulation Distribution and market facilitation index , to decide if GlucoTrack performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days GlucoTrack has generated negative risk-adjusted returns adding no value to investors with long positions. Despite conflicting performance in the last few months, the Stock's basic indicators remain quite persistent which may send shares a bit higher in March 2025. The latest mess may also be a sign of long-standing up-swing for the company institutional investors. ...more
Last Split Factor 1:5 | Last Split Date 2024-05-20 |
1 | GlucoTrack, Inc. Short Interest Down 12.0 percent in October | 11/01/2024 |
2 | Glucotrack announces pricing of 10M public offering | 11/13/2024 |
3 | Glucotrack, Inc. Announces Closing of 10.0 Million Public Offering and Concurrent Private Placement Converting 4.0 in Outstanding Debt - The Manila Times | 11/15/2024 |
4 | U.S. stocks mixed at close of trade Dow Jones Industrial Average up 0.11 percent - MSN | 11/20/2024 |
5 | GLUCOTRACK ANNOUNCES START OF ENROLLMENT FOR HUMAN CLINICAL STUDY OF CONTINUOUS BLOOD GLUCOSE ... | 12/03/2024 |
6 | Glucotrack inks sales agreement for 8.23M stock offering | 12/18/2024 |
7 | Glucotrack to Present at TechBio Showcase 2025 | 01/07/2025 |
8 | Glucotrack issues new shares for warrant exchange | 01/14/2025 |
9 | 12 Health Care Stocks Moving In Fridays Pre-Market Session - Benzinga | 01/17/2025 |
10 | 12 Health Care Stocks Moving In Thursdays Pre-Market Session - Benzinga | 01/30/2025 |
| Begin Period Cash Flow | 2.3 M |
GlucoTrack |
GlucoTrack Relative Risk vs. Return Landscape
If you would invest 116.00 in GlucoTrack on November 2, 2024 and sell it today you would lose (108.90) from holding GlucoTrack or give up 93.88% of portfolio value over 90 days. GlucoTrack is currently does not generate positive expected returns and assumes 17.6577% risk (volatility on return distribution) over the 90 days horizon. In different words, most equities are less risky than GlucoTrack, and most traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
GlucoTrack Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for GlucoTrack's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as GlucoTrack, and traders can use it to determine the average amount a GlucoTrack's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.1343
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | GCTK |
Estimated Market Risk
| 17.66 actual daily | 96 96% of assets are less volatile |
Expected Return
| -2.37 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.13 actual daily | 0 Most of other assets perform better |
Based on monthly moving average GlucoTrack is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of GlucoTrack by adding GlucoTrack to a well-diversified portfolio.
GlucoTrack Fundamentals Growth
GlucoTrack Stock prices reflect investors' perceptions of the future prospects and financial health of GlucoTrack, and GlucoTrack fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on GlucoTrack Stock performance.
| Return On Equity | -5.41 | ||||
| Return On Asset | -1.57 | ||||
| Current Valuation | 3.05 M | ||||
| Shares Outstanding | 16.05 M | ||||
| Price To Book | 21.40 X | ||||
| Gross Profit | (20 K) | ||||
| EBITDA | (7.09 M) | ||||
| Net Income | (7.1 M) | ||||
| Cash And Equivalents | 3.85 M | ||||
| Cash Per Share | 0.25 X | ||||
| Total Debt | 196 K | ||||
| Debt To Equity | 0.06 % | ||||
| Current Ratio | 4.52 X | ||||
| Book Value Per Share | 0.77 X | ||||
| Cash Flow From Operations | (6.56 M) | ||||
| Earnings Per Share | (2.91) X | ||||
| Market Capitalization | 1.14 M | ||||
| Total Asset | 4.91 M | ||||
| Retained Earnings | (109.85 M) | ||||
| Working Capital | 3.36 M | ||||
About GlucoTrack Performance
By examining GlucoTrack's fundamental ratios, stakeholders can obtain critical insights into GlucoTrack's financial health, operational efficiency, and overall profitability. These insights assist in making well-informed investment and management decisions. For example, a high Return on Assets and Return on Equity would indicate that GlucoTrack is effectively utilizing its assets and equity to generate significant profits, enhancing its appeal to investors. On the other hand, low ROA and ROE values could reveal issues in asset and equity management, highlighting the need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 2.5 K | 3.5 K | |
| Return On Tangible Assets | (1.30) | (1.37) | |
| Return On Capital Employed | (2.41) | (2.29) | |
| Return On Assets | (1.30) | (1.37) | |
| Return On Equity | (2.55) | (2.43) |
Things to note about GlucoTrack performance evaluation
Checking the ongoing alerts about GlucoTrack for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for GlucoTrack help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| GlucoTrack generated a negative expected return over the last 90 days | |
| GlucoTrack has high historical volatility and very poor performance | |
| GlucoTrack has some characteristics of a very speculative penny stock | |
| GlucoTrack has a very high chance of going through financial distress in the upcoming years | |
| Net Loss for the year was (7.1 M) with loss before overhead, payroll, taxes, and interest of (20 K). | |
| GlucoTrack currently holds about 3.85 M in cash with (6.56 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.25, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| GlucoTrack has a poor financial position based on the latest SEC disclosures | |
| Roughly 35.0% of the company shares are held by company insiders | |
| Latest headline from news.google.com: 12 Health Care Stocks Moving In Thursdays Pre-Market Session - Benzinga |
- Analyzing GlucoTrack's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether GlucoTrack's stock is overvalued or undervalued compared to its peers.
- Examining GlucoTrack's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating GlucoTrack's management team can have a significant impact on its success or failure. Reviewing the track record and experience of GlucoTrack's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of GlucoTrack's stock. These opinions can provide insight into GlucoTrack's potential for growth and whether the stock is currently undervalued or overvalued.
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in GlucoTrack. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. For more information on how to buy GlucoTrack Stock please use our How to buy in GlucoTrack Stock guide.You can also try the Portfolio Anywhere module to track or share privately all of your investments from the convenience of any device.
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of GlucoTrack. If investors know GlucoTrack will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about GlucoTrack listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of GlucoTrack is measured differently than its book value, which is the value of GlucoTrack that is recorded on the company's balance sheet. Investors also form their own opinion of GlucoTrack's value that differs from its market value or its book value, called intrinsic value, which is GlucoTrack's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because GlucoTrack's market value can be influenced by many factors that don't directly affect GlucoTrack's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between GlucoTrack's value and its price as these two are different measures arrived at by different means. Investors typically determine if GlucoTrack is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, GlucoTrack's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.